Literature DB >> 1646402

Reduced binding of TFIID to transcriptionally compromised mutants of VP16.

C J Ingles1, M Shales, W D Cress, S J Triezenberg, J Greenblatt.   

Abstract

Activator proteins that control transcription initiation by RNA polymerase II usually have two domains: one binds to DNA, and the other activates transcription. A particularly potent acidic activation domain at the C terminus of the herpes simplex virus protein VP16 binds directly and selectively to the human and yeast TATA box-binding factor TFIID. We have now investigated the biological significance of this in vitro interaction by using mutant forms of VP16. For changes at the critical phenylalanine residue at position 442 of VP16 there was a good correlation between transactivation activity in vivo and the binding of VP16 to TFIID in vitro. In contrast, mutants with reduced negative charge were more defective for binding than for activation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646402     DOI: 10.1038/351588a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  163 in total

1.  Positive and negative regulation of endogenous genes by designed transcription factors.

Authors:  R R Beerli; B Dreier; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  The VP16 paradox: herpes simplex virus VP16 contains a long-range activation domain but within the natural multiprotein complex activates only from promoter-proximal positions.

Authors:  M Hagmann; O Georgiev; W Schaffner
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Photo-cross-linking of a purified preinitiation complex reveals central roles for the RNA polymerase II mobile clamp and TFIIE in initiation mechanisms.

Authors:  Diane Forget; Marie-France Langelier; Cynthia Thérien; Vincent Trinh; Benoit Coulombe
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

4.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

5.  The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16.

Authors:  J M Hardwick; L Tse; N Applegren; J Nicholas; M A Veliuona
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

6.  The ability to associate with activation domains in vitro is not required for the TATA box-binding protein to support activated transcription in vivo.

Authors:  W P Tansey; W Herr
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

7.  The activation domain of GAL4 protein mediates cooperative promoter binding with general transcription factors in vivo.

Authors:  S Vashee; T Kodadek
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

8.  The extreme carboxyl terminus of the equine herpesvirus 1 homolog of herpes simplex virus VP16 is essential for immediate-early gene activation.

Authors:  G D Elliott
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Proline-rich activator CTF1 targets the TFIIB assembly step during transcriptional activation.

Authors:  T K Kim; R G Roeder
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

10.  The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription.

Authors:  X Liu; C W Miller; P H Koeffler; A J Berk
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.